Inclisiran receives reimbursement and enters clinical practice
Authors:
Kristýna Čillíková
Authors‘ workplace:
Česká společnost pro aterosklerózu
Published in:
AtheroRev 2023; 8(2): 117-120
Category:
Announcements
Sources
1. Ray KK, Kallend D, Leiter LA et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J 2022; 43(48): 5047–5057. <https://doi.org/10.1093/eurheartj/ehac615>.
2. Wright RS, Ray KK et al. Impact of Inclisiran on LDL-C Over 18 months in Patients With ASCVD or Risk-Equivalent - ORION-11. American College of Cardiology. Dostupné z WWW: <https://www.acc.org/latest-in-cardiology/ clinical-trials/2019/09/01/12/22/orion-11>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsArticle was published in
Athero Review
2023 Issue 2
Most read in this issue
- Bempedoic acid in the context of current hypolipidemic treatment options and the results of the CLEAR OUTCOMES trial
- Statement CSAT on Consensus statement of the European Atherosclerosis Society: Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis
- The importance of nonstatin therapies for LDL-cholesterol lowering in the management of very high and high atherosclerotic cardiovascular risk
- Hyperlipidemic crisis as a risk factor for acute pancreatitis